{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:29:45Z","timestamp":1790188185427,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Resolution is an active process that protects the host damage from inflammation responses induced by infections. Simultaneously resolving inflammation and eliminating pathogens may be effective to treat infectious diseases, but it is required to deliver therapeutics to infectious sites. Here, we proposed a strategy to incorporate RvD1 and an antibiotic (ceftazidime) in human neutrophil-membrane derived nanovesicles that can specifically target inflamed vasculature for treatment of lung infection caused by <jats:italic>P. aeruginosa<\/jats:italic>. Using the nitrogen cavitation method, we generated liposome-like nanovesicles from human neutrophil membrane. The results showed that nanovesicles loaded with RvD1 decreased cytokine levels and neutrophil lung infiltration, thus shortening the resolution intervals of lung inflammation. When RvD1 and ceftazidime were co-loaded in nanovesicles, they alleviated both inflammation and bacterial growth in the mouse lung. The studies reveal a new strategy to treat infectious diseases by designing nanoparticles to simultanesouly\u00a0target host inflammatory pathways and pathogens.<\/jats:p>","DOI":"10.1038\/s42003-020-01410-5","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T11:04:19Z","timestamp":1605524659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Co-delivery of resolvin D1 and antibiotics with nanovesicles to lungs resolves inflammation and clears bacteria in mice"],"prefix":"10.1038","volume":"3","author":[{"given":"Jin","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon G.","family":"Leanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8960-8896","authenticated-orcid":false,"given":"Tianhong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-1935","authenticated-orcid":false,"given":"Zhenjia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"1410_CR1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.annder.2017.06.015","volume":"144","author":"A Morand","year":"2017","unstructured":"Morand, A. & Morand, J. J. Pseudomonas aeruginosa in dermatology. Ann. Dermatol Vener. 144, 666\u2013675 (2017).","journal-title":"Ann. Dermatol Vener."},{"key":"1410_CR2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jmii.2015.06.003","volume":"50","author":"CH Lee","year":"2017","unstructured":"Lee, C. H. et al. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems. J. Microbiol. Immunol. Infect. 50, 677\u2013683 (2017).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"1410_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli, Y. et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect. Dis. 16, 661\u2013673 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"1410_CR4","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.4049\/jimmunol.176.8.4923","volume":"176","author":"RT Sadikot","year":"2006","unstructured":"Sadikot, R. T. et al. Targeted immunomodulation of the NF-kappaB pathway in airway epithelium impacts host defense against Pseudomonas aeruginosa. J. Immunol. 176, 4923\u20134930 (2006).","journal-title":"J. Immunol."},{"key":"1410_CR5","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1164\/rccm.201206-1063PP","volume":"186","author":"JP Mizgerd","year":"2012","unstructured":"Mizgerd, J. P. Respiratory infection and the impact of pulmonary immunity on lung health and disease. Am. J. Respir. Crit. Care Med. 186, 824\u2013829 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1410_CR6","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1172\/JCI60331","volume":"122","author":"MA Matthay","year":"2012","unstructured":"Matthay, M. A., Ware, L. B. & Zimmerman, G. A. The acute respiratory distress syndrome. J. Clin. Invest. 122, 2731\u20132740 (2012).","journal-title":"J. Clin. Invest."},{"key":"1410_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/annurev-pathol-011110-130158","volume":"6","author":"MA Matthay","year":"2011","unstructured":"Matthay, M. A. & Zemans, R. L. The acute respiratory distress syndrome: pathogenesis and treatment. Annu. Rev. Pathol. 6, 147\u2013163 (2011).","journal-title":"Annu. Rev. Pathol."},{"key":"1410_CR8","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1056\/NEJMcp052699","volume":"353","author":"LB Ware","year":"2005","unstructured":"Ware, L. B. & Matthay, M. A. Clinical practice. Acute pulmonary edema. N. Engl. J. Med 353, 2788\u20132796 (2005).","journal-title":"N. Engl. J. Med"},{"key":"1410_CR9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMra1608077","volume":"377","author":"BT Thompson","year":"2017","unstructured":"Thompson, B. T., Chambers, R. C. & Liu, K. D. Acute respiratory distress syndrome. N. Engl. J. Med. 377, 562\u2013572 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1410_CR10","doi-asserted-by":"publisher","unstructured":"Roope, L. S. J. et al. The challenge of antimicrobial resistance: what economics can contribute. Science 364, https:\/\/doi.org\/10.1126\/science.aau4679 (2019).","DOI":"10.1126\/science.aau4679"},{"key":"1410_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1051\/vetres:2001127","volume":"32","author":"FM Aarestrup","year":"2001","unstructured":"Aarestrup, F. M. & Engberg, J. Antimicrobial resistance of thermophilic Campylobacter. Vet. Res 32, 311\u2013321 (2001).","journal-title":"Vet. Res"},{"key":"1410_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.drup.2017.07.003","volume":"31","author":"N Kashef","year":"2017","unstructured":"Kashef, N. & Hamblin, M. R. Can microbial cells develop resistance to oxidative stress in antimicrobial photodynamic inactivation? Drug Resist. Updat. 31, 31\u201342 (2017).","journal-title":"Drug Resist. Updat."},{"key":"1410_CR13","doi-asserted-by":"publisher","unstructured":"Dong, X. Y., Zhang, C. Y., Gao, J. & Wang, Z. J. Targeting of nanotherapeutics to infection sites for antimicrobial therapy. Adv. Ther. Germany 2, UNSP 1900095 https:\/\/doi.org\/10.1002\/adtp.201900095 (2019).","DOI":"10.1002\/adtp.201900095"},{"key":"1410_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41551-017-0187-5","volume":"2","author":"S Hussain","year":"2018","unstructured":"Hussain, S. et al. Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy. Nat. Biomed. Eng. 2, 95\u2013103 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"1410_CR15","doi-asserted-by":"publisher","first-page":"e1803618","DOI":"10.1002\/adma.201803618","volume":"30","author":"CY Zhang","year":"2018","unstructured":"Zhang, C. Y., Gao, J. & Wang, Z. Bioresponsive nanoparticles targeted to infectious microenvironments for sepsis management. Adv. Mater. 30, e1803618 (2018).","journal-title":"Adv. Mater."},{"key":"1410_CR16","doi-asserted-by":"publisher","first-page":"16380","DOI":"10.1021\/acsami.9b04051","volume":"11","author":"CY Zhang","year":"2019","unstructured":"Zhang, C. Y. et al. pH-responsive nanoparticles targeted to lungs for improved therapy of acute lung inflammation\/injury. ACS Appl. Mater. Interfaces 11, 16380\u201316390 (2019).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"1410_CR17","doi-asserted-by":"publisher","first-page":"eaax7964","DOI":"10.1126\/sciadv.aax7964","volume":"5","author":"CY Zhang","year":"2019","unstructured":"Zhang, C. Y. et al. Nanoparticle-induced neutrophil apoptosis increases survival in sepsis and alleviates neurological damage in stroke. Sci. Adv. 5, eaax7964 (2019).","journal-title":"Sci. Adv."},{"key":"1410_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1126\/science.1230720","volume":"339","author":"I Tabas","year":"2013","unstructured":"Tabas, I. & Glass, C. K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339, 166\u2013172 (2013).","journal-title":"Science"},{"key":"1410_CR19","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/nm.2514","volume":"17","author":"M Phillipson","year":"2011","unstructured":"Phillipson, M. & Kubes, P. The neutrophil in vascular inflammation. Nat. Med. 17, 1381\u20131390 (2011).","journal-title":"Nat. Med."},{"key":"1410_CR20","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1182\/blood-2008-01-078204","volume":"111","author":"DD Wagner","year":"2008","unstructured":"Wagner, D. D. & Frenette, P. S. The vessel wall and its interactions. Blood 111, 5271\u20135281 (2008).","journal-title":"Blood"},{"key":"1410_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nnano.2014.17","volume":"9","author":"ZJ Wang","year":"2014","unstructured":"Wang, Z. J., Li, J., Cho, J. & Malik, A. B. Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils. Nat. Nanotechnol. 9, 204\u2013210 (2014).","journal-title":"Nat. Nanotechnol."},{"key":"1410_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jconrel.2016.01.024","volume":"224","author":"J Gao","year":"2016","unstructured":"Gao, J., Chu, D. F. & Wang, Z. J. Cell membrane-formed nanovesicles for disease-targeted delivery. J. Control Release 224, 208\u2013216 (2016).","journal-title":"J. Control Release"},{"key":"1410_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.biomaterials.2017.05.003","volume":"135","author":"J Gao","year":"2017","unstructured":"Gao, J., Wang, S. H. & Wang, Z. J. High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy. Biomaterials 135, 62\u201373 (2017).","journal-title":"Biomaterials"},{"key":"1410_CR24","doi-asserted-by":"publisher","unstructured":"Dong, X. et al. Neutrophil membrane-derived nanovesicles alleviate inflammation to protect mouse brain injury from ischemic stroke. ACS Nano, https:\/\/doi.org\/10.1021\/acsnano.8b06572 (2019).","DOI":"10.1021\/acsnano.8b06572"},{"key":"1410_CR25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1084\/jem.20020760","volume":"196","author":"CN Serhan","year":"2002","unstructured":"Serhan, C. N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025\u20131037 (2002).","journal-title":"J. Exp. Med."},{"key":"1410_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1172\/JCI42545","volume":"121","author":"SF Oh","year":"2011","unstructured":"Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R. & Serhan, C. N. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. 121, 569\u2013581 (2011).","journal-title":"J. Clin. Invest."},{"key":"1410_CR27","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/nature08541","volume":"461","author":"M Spite","year":"2009","unstructured":"Spite, M. et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287\u20131291 (2009).","journal-title":"Nature"},{"key":"1410_CR28","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ajpath.2012.01.028","volume":"180","author":"S Krishnamoorthy","year":"2012","unstructured":"Krishnamoorthy, S., Recchiuti, A., Chiang, N., Fredman, G. & Serhan, C. N. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am. J. Pathol. 180, 2018\u20132027 (2012).","journal-title":"Am. J. Pathol."},{"key":"1410_CR29","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1073\/pnas.0907342107","volume":"107","author":"S Krishnamoorthy","year":"2010","unstructured":"Krishnamoorthy, S. et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl Acad. Sci. USA 107, 1660\u20131665 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1410_CR30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature11042","volume":"484","author":"N Chiang","year":"2012","unstructured":"Chiang, N. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524\u2013528 (2012).","journal-title":"Nature"},{"key":"1410_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1021\/mp800051m","volume":"5","author":"F Alexis","year":"2008","unstructured":"Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharmaceutics 5, 505\u2013515 (2008).","journal-title":"Mol. Pharmaceutics"},{"key":"1410_CR32","doi-asserted-by":"publisher","first-page":"14075","DOI":"10.1002\/anie.201707598","volume":"56","author":"X Zhang","year":"2017","unstructured":"Zhang, X. et al. Remote loading of small-molecule therapeutics into cholesterol-enriched cell-membrane-derived vesicles. Angew. Chem. 56, 14075\u201314079 (2017).","journal-title":"Angew. Chem."},{"key":"1410_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.biomaterials.2017.02.041","volume":"128","author":"RH Fang","year":"2017","unstructured":"Fang, R. H., Jiang, Y., Fang, J. C. & Zhang, L. Cell membrane-derived nanomaterials for biomedical applications. Biomaterials 128, 69\u201383 (2017).","journal-title":"Biomaterials"},{"key":"1410_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nri3399","volume":"13","author":"E Kolaczkowska","year":"2013","unstructured":"Kolaczkowska, E. & Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13, 159\u2013175 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"1410_CR35","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.clinbiochem.2007.12.021","volume":"41","author":"M Freitas","year":"2008","unstructured":"Freitas, M., Porto, G., Lima, J. L. & Fernandes, E. Isolation and activation of human neutrophils in vitro. The importance of the anticoagulant used during blood collection. Clin. Biochem. 41, 570\u2013575 (2008).","journal-title":"Clin. Biochem."},{"key":"1410_CR36","doi-asserted-by":"publisher","first-page":"e26004","DOI":"10.1371\/journal.pone.0026004","volume":"6","author":"ML Fermino","year":"2011","unstructured":"Fermino, M. L. et al. LPS-induced galectin-3 oligomerization results in enhancement of neutrophil activation. PLoS ONE 6, e26004 (2011).","journal-title":"PLoS ONE"},{"key":"1410_CR37","doi-asserted-by":"publisher","first-page":"17181","DOI":"10.1073\/pnas.0905181106","volume":"106","author":"A Briegel","year":"2009","unstructured":"Briegel, A. et al. Universal architecture of bacterial chemoreceptor arrays. Proc. Natl Acad. Sci. USA 106, 17181\u201317186 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1410_CR38","doi-asserted-by":"publisher","first-page":"e1706245","DOI":"10.1002\/adma.201706245","volume":"30","author":"D Chu","year":"2018","unstructured":"Chu, D., Dong, X., Shi, X., Zhang, C. & Wang, Z. Neutrophil-based drug delivery systems. Adv. Mater. 30, e1706245 (2018).","journal-title":"Adv. Mater."},{"key":"1410_CR39","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nri2156","volume":"7","author":"K Ley","year":"2007","unstructured":"Ley, K., Laudanna, C., Cybulsky, M. I. & Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678\u2013689 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"1410_CR40","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.immuni.2014.10.008","volume":"41","author":"S Nourshargh","year":"2014","unstructured":"Nourshargh, S. & Alon, R. Leukocyte migration into inflamed tissues. Immunity 41, 694\u2013707 (2014).","journal-title":"Immunity"},{"key":"1410_CR41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(06)69005-3","volume":"368","author":"KA Brown","year":"2006","unstructured":"Brown, K. A. et al. Neutrophils in development of multiple organ failure in sepsis. Lancet 368, 157\u2013169 (2006).","journal-title":"Lancet"},{"key":"1410_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nri1785","volume":"6","author":"C Nathan","year":"2006","unstructured":"Nathan, C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 6, 173\u2013182 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"1410_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1146\/annurev.immunol.25.022106.141647","volume":"25","author":"CN Serhan","year":"2007","unstructured":"Serhan, C. N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25, 101\u2013137 (2007).","journal-title":"Annu. Rev. Immunol."},{"key":"1410_CR44","doi-asserted-by":"publisher","first-page":"836","DOI":"10.4049\/jimmunol.0901809","volume":"184","author":"H Seki","year":"2010","unstructured":"Seki, H. et al. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J. Immunol. 184, 836\u2013843 (2010).","journal-title":"J. Immunol."},{"key":"1410_CR45","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.coph.2013.05.012","volume":"13","author":"CN Serhan","year":"2013","unstructured":"Serhan, C. N. & Chiang, N. Resolution phase lipid mediators of inflammation: agonists of resolution. Curr. Opin. Pharmacol. 13, 632\u2013640 (2013).","journal-title":"Curr. Opin. Pharmacol."},{"key":"1410_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0003-2697(80)90269-9","volume":"104","author":"JC Stewart","year":"1980","unstructured":"Stewart, J. C. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104, 10\u201314 (1980).","journal-title":"Anal. Biochem."},{"key":"1410_CR47","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1001\/archinte.1959.00270010010002","volume":"103","author":"MJ Albrink","year":"1959","unstructured":"Albrink, M. J. & Man, E. B. Serum triglycerides in coronary artery disease. AMA Arch. Intern. Med. 103, 4\u20138 (1959).","journal-title":"AMA Arch. Intern. Med."},{"key":"1410_CR48","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/170626a0","volume":"170","author":"WE Trevelyan","year":"1952","unstructured":"Trevelyan, W. E., Forrest, R. S. & Harrison, J. S. Determination of yeast carbohydrates with the anthrone reagent. Nature 170, 626\u2013627 (1952).","journal-title":"Nature"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01410-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01410-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01410-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T03:06:06Z","timestamp":1670382366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01410-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["1410"],"URL":"https:\/\/doi.org\/10.1038\/s42003-020-01410-5","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"11 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.W. and J.G. declare a patent pending on this delivery strategy. All other authors (S.W., X.D., L.G.L., and T.D.) declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"680"}}